"TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure".

Horton JS, Shiraishi T, Alfulaij N, Small-Howard AL, Turner HC, Kurokawa T, Mori Y, Stokes AJ. "TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure". Channels (Austin). 2019 12; 13(1):1-16.

View in: PubMed

subject areas

Acrylamides
Administration, Oral
Animals
Cardiomegaly
Heart Failure
Humans
Male
Mice
Mice, Inbred C57BL
Molecular Structure
Signal Transduction
TRPV Cation Channels

authors with profiles

Naghum Alfulaij, PhD
Alexander J. Stokes, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support